Angiex Partners with Abzena for Phase I Trial of AGX101 Solid Tumor Therapy
Angiex has partnered with Abzena to advance the Phase I trial of AGX101, a novel TM4SF1-targeted antibody-drug conjugate (ADC) designed to treat solid tumors by targeting the blood vessels that supply them. This collaboration with Abzena, known for its expertise in biopharmaceutical manufacturing, is a critical component in ensuring the success of the early-stage clinical trial, as Angiex works to bring this innovative cancer therapy to patients with aggressive solid tumors.
PharmTech covered the collaboration, emphasizing the importance of strategic partnerships in clinical development. A highly regarded source for pharmaceutical manufacturing and development news, PharmTech highlighted how collaborations between biotech companies and CDMOs like Abzena are vital for pushing the boundaries of oncology research. Their coverage underscores the potential of AGX101 to make a significant impact in the treatment of solid tumors.